NASDAQ:ADXS - Advaxis Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.34 +0.12 (+9.84 %) (As of 07/15/2018 04:00 PM ET)Previous Close$1.34Today's Range$1.30 - $1.6252-Week Range$1.15 - $7.45Volume6.98 million shsAverage Volume809,756 shsMarket Capitalization$70.51 millionP/E Ratio-0.58Dividend YieldN/ABeta1.42 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey. Receive ADXS News and Ratings via Email Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ADXS CUSIPN/A Webwww.advaxis.com Phone609-452-9813 Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio3.47 Price-To-Earnings Trailing P/E Ratio-0.58 Forward P/E Ratio-1.23 P/E GrowthN/A Sales & Book Value Annual Sales$12.03 million Price / Sales5.86 Cash FlowN/A Price / CashN/A Book Value$1.32 per share Price / Book1.02 Profitability EPS (Most Recent Fiscal Year)($2.31) Net Income$-93,430,000.00 Net Margins-1,041.73% Return on Equity-168.35% Return on Assets-99.50% Miscellaneous Employees108 Outstanding Shares52,620,000Market Cap$70.51 Advaxis (NASDAQ:ADXS) Frequently Asked Questions What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." How were Advaxis' earnings last quarter? Advaxis, Inc. (NASDAQ:ADXS) posted its quarterly earnings results on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to analysts' expectations of $3.03 million. Advaxis had a negative return on equity of 168.35% and a negative net margin of 1,041.73%. View Advaxis' Earnings History. When is Advaxis' next earnings date? Advaxis is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Advaxis. What price target have analysts set for ADXS? 3 brokers have issued twelve-month target prices for Advaxis' shares. Their predictions range from $2.00 to $5.00. On average, they expect Advaxis' stock price to reach $3.3333 in the next year. This suggests a possible upside of 148.8% from the stock's current price. View Analyst Ratings for Advaxis. What is the consensus analysts' recommendation for Advaxis? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Advaxis stock? Here are some recent quotes from research analysts about Advaxis stock: 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year- end 2018 net cash of $2.17/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x. We use a 25% discount rate for the pipeline, which includes CCX140, CCX872 and avacopan for HS, as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development. We project revenues of $72M for avacopan in AAV in 2021, growing to $1.4B in 2028. For avacopan in C3G, we estimate revenues of $10M in 2024, increasing to $124M in 2028." (6/8/2018) 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017) Are investors shorting Advaxis? Advaxis saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 2,750,913 shares, a decrease of 32.8% from the June 15th total of 4,095,674 shares. Based on an average daily trading volume, of 1,051,998 shares, the days-to-cover ratio is currently 2.6 days. Approximately 5.8% of the shares of the company are short sold. View Advaxis' Current Options Chain. Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include Zafgen (ZFGN), Ovid Therapeutics (OVID), DURECT (DRRX), Avadel Pharmaceuticals (AVDL), Kadmon (KDMN), Avid Bioservices (CDMO), resTORbio (TORC), Neptune Technologies & Bioressources (NEPT), Strongbridge Biopharma (SBBP), Galectin Therapeutics Inc. Common Stock (GALT), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Ocular Therapeutix (OCUL), Galmed Pharmaceuticals (GLMD), CTI BioPharma (CTIC) and Cue Biopharma (CUE). Who are Advaxis' key executives? Advaxis' management team includes the folowing people: Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)Mr. Anthony A. Lombardo, Exec. Officer (Age 69)Mr. Kenneth A. Berlin, Pres, CEO and Director (Age 54)Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 47)Mr. Mayo Pujols, Sr. VP of Technical Operations Has Advaxis been receiving favorable news coverage? News headlines about ADXS stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Advaxis earned a media sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Advaxis' stock price today? One share of ADXS stock can currently be purchased for approximately $1.34. How big of a company is Advaxis? Advaxis has a market capitalization of $70.51 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe. How can I contact Advaxis? Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected] MarketBeat Community Rating for Advaxis (NASDAQ ADXS)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 242 (Vote Outperform)Underperform Votes: 148 (Vote Underperform)Total Votes: 390MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?